NASDAQ:GELS 14 January 2026

May 2, 2026, 12:25 PM EDT. Guardant Health (GH) trades near US$87.60, down 1.5% last week and 3.9% over a month, yet up 87% in the past year. Despite a 35.3% drop over five years, its multi-year gains reflect strong market interest in its healthcare diagnostics technology. A Discounted Cash Flow (DCF) model estimates GH's intrinsic value at approximately US$173.89 per share, suggesting it is undervalued by nearly 50%. This model projects free cash flow turning positive by 2030, highlighting long-term growth potential. Given negative current free cash flow, Price-to-Sales (P/S) ratios are used as alternative valuation metrics. Guardant Health's valuation score of 3 out of 6 indicates moderate potential, balancing recent pullbacks against solid longer-term returns and prospects.